April 17 (Reuters) - Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday. (Reporting by Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)